Share this link via:
Viscosupplementation Market size was valued at USD 7.9 Billion in 2023 and is projected to reach USD 17.50 Billion by 2032, growing at a CAGR of 9.24% from 2024 to 2032.
Viscosupplementation is used mainly in the treatment for osteoarthritis and consists of an injection of medication in the form of gel into the joint. The therapeutic outcome is the reduction of pain, an improved joint function, and quality of life in patients with this degenerative disease. Viscosupplementation generally involves the use of a gel, most commonly hyaluronic acid, which acts as a natural body chemical that is present in the joint fluid normally and serves as a lubricant to reduce friction. In effect, during the course of osteoarthritis, there is a reduction of hyaluronic acid in the joint fluid. Therefore, viscosupplementation helps to return the normal fluidity of synovial fluid and, subsequently, reduce the friction and RAISE mobility.
The 1980s marked the beginning of viscosupplementation when the first studies were conducted to investigate the effectiveness of HA injections in the treatment of joint diseases. The application has continually been accepted over the years, and it is now considered as a routine and conventional treatment method for the management of knee osteoarthritis. Extensive research has enlarged the application of the application of the above treatment form to the hip, shoulder, and ankle joints. Treatment for most products is conducted in a series of injections, but the number and time frame for the injections/printing vary with each product and are dependent on severity of the condition being treated.
Results vary from patient to patient, but many patients have been found to benefit with tremendous relief from pain as well as increased joint mobility subsequent to viscosupplementation. Clinical trials have proven that these benefits are long-lasting, from 6 to more than 12 months, based on patient-specific factors and the type of hyaluronic acid. Moreover, the procedure is minimally invasive and hence carries fewer risks than the more invasive or non-surgical options available, so it is highly favored for most of the patients who are still not candidates for surgery.
Viscosupplementation, despite being beneficial, has its limits. The procedure does not halt the degenerative process of OA or regenerate the damaged cartilage. This rather acts as a symptomatic treatment modality, which can be an add-on along with other therapies, which include physical therapy, lifestyle changes, and medications. This can also hold implications for patient-to-patient variability in effect and the requirement for a treatment series with all the attendant limitation this implies for the patient and health care provider.
A growing awareness of osteoarthritis and demand for effective, minimally invasive treatment are resulting in the growth of the viscosupplementation market. As further improvement is shown in the preparation of HA and the techniques of delivery, its safety and efficacy would further improve, making it an expanding use in clinical practice. Further, studies on the alternative viscosupplementation agents in their pros and cons are under study, likely to shape the outlook of the market in near future. Because of increasing age and prevalence of osteoarthritis, the use of viscosupplementation will grow to be vital in the maintenance of joint health and quality of life among patients.
In November 2022, Anika Therapeutics, Inc., a prominent company in joint preservation, has achieved the primary objective in the Phase III study for its drug, Cingal. This medication aims to offer extended pain relief for individuals suffering from knee osteoarthritis (OA). Securing FDA approval and launching Cingal in the United States are key goals for the company. Successful clinical trials like this enhance an organization’s research and development capabilities, providing a significant competitive edge in the market.
The report will cover the qualitative and quantitative data on the global Viscosupplementation Market. The qualitative data includes latest trends, market players analysis, market drivers, market opportunity, and many others. Also, the report quantitative data includes market size for every region, country, and segments according to your requirements. We can also provide customize report in every industry vertical.
Study Period | 2024-32 |
Base Year | 2023 |
Estimated Forecast Year | 2024-32 |
Growth Rate | CAGR of 9.24% from 2024 to 2032 |
Segmentation | By Product, By End-use, By Region |
Unit | USD Billion |
By Product |
|
By End-use |
|
By Region |
|
The market scope is segmented because of by Product, by End-use.
Based on the Product of the market is segmented into Single Injection, Three Injection, Five Injection.
The three-injection segment has always been the leading product segment in the viscosupplementation market. It can be attributed to the balance it strikes between its effectiveness and patient compliance, which are definitely more cost-effective. Providing a realistic middle course to single and five injections, the three-injection course stretches the period of relief adequately to about six months, which tallies well with the usual intervals for treatment courses that are required to manage osteoarthritic symptoms. This has greatly elevated its favour as it can really provide the promise of effective pain alleviation and improvement in joint function without excessively frequent or long treatment schedules.
Certainly, products requiring a single injection are more convenient and less costly up front, but they generally provide shorter-term relief and require more frequent re-treatment, all of which impacts the overall compliance by patients and long-term cost-efficacy. On the other end, five-injection regimens have extended relief and fewer injections overall but are generally more expensive and less appealing to patients who are hesitant about the duration and frequency of treatment.
Based on the End-use of the market is segmented into Hospitals, Orthopaedic Clinics/ASCs.
Orthopaedic clinics and ASCs have turned out to be the dominant end-use segments in the viscosupplementation market. Now, why is that? First of all, orthopaedic clinics and ASCs are concerned with the treatment of musculoskeletal disorders such as osteoarthritis, the very reason for which viscosupplementation procedures are performed. The infusion facilities are endowed with the necessary experience and infrastructure to deliver focused and potent treatments that attract a high number of patients seeking relief from various joint aches and mobility complications.
These orthopaedic clinics and ASCs will, in turn, host a wide array of specialty services targeting the problems of the patient at large. These shall include advanced diagnostic tools and minimally invasive procedures. This means that there will be a more concentrated, efficient focus on viscosupplementation, thus ultimately yielding improved patient outcomes and increased patient satisfaction. Moreover, the trend toward outpatient care and increasing preference for minimally invasive procedures have further enhanced the role of ASCs in the viscosupplementation market. Generally, ASCs offer less recovery time and are associated with lower costs compared to a hospital setting—hence, more attractive to both patients and payers.
It provides the analysis of markets in North America, Europe, Asia-Pacific, Latin America, and MEA by region. North America has historically held the largest share of the viscosupplementation market and is anticipated to continue doing so during the forecast period, owing to several influencing factors. First, this region dominates the market due to the developed healthcare infrastructure in this region, then it is followed by the presence of a huge aging population affected by osteoarthritis, and finally, it is further supported by substantial investment in medical research and development. North America, in particular the United States, offers a much-established market for viscosupplementation treatment procedures, as it is well-endowed with advanced treatment facilities and presents a high level of patient awareness. Moreover, some leading pharmaceuticals and medical devices companies are operating within this region as well, thereby strengthening its lead on the global market through innovation, continuity, and a constant supply of new innovative products.
The fastest-growing viscosupplementation market, however, is expected to be that of the Asia-Pacific region in the near future. Factors driving such growth include the increasing population, rising prevalence of osteoarthritis, and increased spending on healthcare in the region. With a growing middle class and enhanced disposable incomes, there exists an increased demand for better healthcare services and treatment procedures. Furthermore, betterment in healthcare infrastructure and access to medical technologies in countries like China, India, and Japan are providing a conducive environment for the adoption of viscosupplementation therapies in such countries. Increasing awareness and acceptance of advanced treatments among such emerging economies further accelerate their growth. Hence, the Asia-Pacific region is projected to show considerable market growth due to these highly dynamic and changing variables.
Viscosupplementation Market Report is also available for below Regions and Country Please Ask for that
Viscosupplementation Market Trends: Market key trends which include Increased Competition and Continuous Innovations Trends
You'll get the sample you asked for by email. Remember to check your spam folder as well. If you have any further questions or require additional assistance, feel free to let us know via-
+1 724 648 0810 +91 976 407 9503 sales@intellectualmarketinsights.com
20 Mar 2023
Intellectual Market Insights Research © 2026. All rights reserved.
